Aligos Therapeutics
- Country
- πΊπΈUnited States
- Ownership
- Public
- Established
- 2018-04-12
- Employees
- 66
- Market Cap
- -
- Website
- http://www.aligos.com
- Introduction
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is engaged in in developing therapeutics for chronic liver diseases and viral infections. The firm is focused on the discovery and development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses, as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). The company was founded by Lucinda Quan and Lawrence M. Blatt on February 05, 2018 and is headquartered in South San Francisco, CA.
A Study of ALG-020572 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single Doses in Healthy Volunteers and Multiple Doses in CHB Subjects
- First Posted Date
- 2021-08-11
- Last Posted Date
- 2023-04-25
- Lead Sponsor
- Aligos Therapeutics
- Target Recruit Count
- 40
- Registration Number
- NCT05001022
- Locations
- π³πΏ
Auckland Clinical Studies, Auckland, New Zealand
π¬π§King's College Hospital, London, United Kingdom
π¬π§St George's University of London, London, United Kingdom
A Study of ALG-000184 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single and Multiple Doses in Healthy Volunteers and CHB Subjects
- Conditions
- Chronic Hepatitis B
- Interventions
- First Posted Date
- 2020-09-02
- Last Posted Date
- 2023-04-28
- Lead Sponsor
- Aligos Therapeutics
- Target Recruit Count
- 336
- Registration Number
- NCT04536337
- Locations
- π¦πΊ
Saint Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia
π¬π§King's College Hospital, London, United Kingdom
π¨π³The Second Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing, China
A Study of ALG-010133 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single and Multiple Doses in Healthy Volunteers and CHB Subjects
- First Posted Date
- 2020-07-24
- Last Posted Date
- 2022-03-15
- Lead Sponsor
- Aligos Therapeutics
- Target Recruit Count
- 103
- Registration Number
- NCT04485663
- Locations
- π¨π³
Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong, China
π¨π³The First Hospital of Jilin University, Changchun, Jilin, China
π°π·Pusan National University Hospital, Busan, Korea, Republic of